Ascletis Pharma Inc. Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results

Reuters

Yesterday

<a href="https://laohu8.com/S/ASCLF">Ascletis Pharma Inc.</a> Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results

Ascletis Pharma Inc. has announced the development of ASC30, an investigational GLP-1R biased small molecule agonist designed for both oral and subcutaneous administration. In a U.S. Phase Ib clinical study, ASC30's ultra-long-acting subcutaneous depot formulation demonstrated an observed half-life of 75 days in participants with obesity, supporting once-quarterly administration as a maintenance therapy for chronic weight management. Additionally, the ASC30 treatment formulation has shown an observed half-life of 46 days, indicating potential for once-monthly administration. Topline data from the Phase IIa study for ASC30 treatment formulation are expected in the first quarter of 2026. The company holds patent protection for ASC30, a new chemical entity, until 2044.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2566695088"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566695088\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566695088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566695088","market":"us","top_or_hot":-1,"title":"Ascletis Pharma Inc. Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ascletis Pharma Inc. has announced the development of ASC30, an investigational GLP-1R biased small molecule agonist designed for both oral and subcutaneous administration. In a U.S. Phase Ib clinical study, ASC30's ultra-long-acting subcutaneous depot formulation demonstrated an observed half-life of 75 days in participants with obesity, supporting once-quarterly administration as a maintenance therapy for chronic weight management. Additionally, the ASC30 treatment formulation has shown an observed half-life of 46 days, indicating potential for once-monthly administration. Topline data from the Phase IIa study for ASC30 treatment formulation are expected in the first quarter of 2026. The company holds patent protection for ASC30, a new chemical entity, until 2044.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Inc. Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Inc. Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-09 18:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ascletis Pharma Inc. has announced the development of ASC30, an investigational GLP-1R biased small molecule agonist designed for both oral and subcutaneous administration. In a U.S. Phase Ib clinical study, ASC30's ultra-long-acting subcutaneous depot formulation demonstrated an observed half-life of 75 days in participants with obesity, supporting once-quarterly administration as a maintenance therapy for chronic weight management. Additionally, the ASC30 treatment formulation has shown an observed half-life of 46 days, indicating potential for once-monthly administration. Topline data from the Phase IIa study for ASC30 treatment formulation are expected in the first quarter of 2026. The company holds patent protection for ASC30, a new chemical entity, until 2044.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL9ZnHs1:1","article_id":"2566695088","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566695088","pubTimestamp":1757413314,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascletis Pharma Inc. has announced the development of ASC30, an investigational GLP-1R biased small molecule agonist designed for both oral and subcutaneous administration. In a U.S. Phase Ib clinical study, ASC30's ultra-long-acting subcutaneous depot formulation demonstrated an observed half-life of 75 days in participants with obesity, supporting once-quarterly administration as a maintenance therapy for chronic weight management. Additionally, the ASC30 treatment formulation has shown an observed half-life of 46 days, indicating potential for once-monthly administration. Topline data from the Phase IIa study for ASC30 treatment formulation are expected in the first quarter of 2026. The company holds patent protection for ASC30, a new chemical entity, until 2044.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B","BK1515":"抗疫概念","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"歌礼制药(Ascletis Pharma Inc.)宣布ASC30用于肥胖治疗的IIa期研究，半衰期结果令人鼓舞","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":0.9},"content_text":"Ascletis Pharma Inc. Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results\n    \n\n        Ascletis Pharma Inc. has announced the development of ASC30, an investigational GLP-1R biased small molecule agonist designed for both oral and subcutaneous administration. In a U.S. Phase Ib clinical study, ASC30's ultra-long-acting subcutaneous depot formulation demonstrated an observed half-life of 75 days in participants with obesity, supporting once-quarterly administration as a maintenance therapy for chronic weight management. Additionally, the ASC30 treatment formulation has shown an observed half-life of 46 days, indicating potential for once-monthly administration. Topline data from the Phase IIa study for ASC30 treatment formulation are expected in the first quarter of 2026. The company holds patent protection for ASC30, a new chemical entity, until 2044.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}